{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:54:41Z","timestamp":1768431281039,"version":"3.49.0"},"reference-count":133,"publisher":"Bentham Science Publishers Ltd.","issue":"28","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,10,25]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Immunotherapy by using checkpoint inhibitors is now tried in the\ntreatment of several malignancies, including Acute Myeloid Leukemia (AML). The treatment\nis tried both as monotherapy and as a part of combined therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Relevant publications were identified through literature searches in the PubMed\ndatabase. We searched for (i) original articles describing the results from clinical studies of\ncheckpoint inhibition; (ii) published articles describing the immunocompromised status of\nAML patients; and (iii) published studies of antileukemic immune reactivity and immunotherapy\nin AML.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Studies of monotherapy suggest that checkpoint inhibition has a modest antileukemic\neffect and complete hematological remissions are uncommon, whereas combination with conventional\nchemotherapy increases the antileukemic efficiency with acceptable toxicity. The\nexperience with a combination of different checkpoint inhibitors is limited. Thalidomide derivatives\nare referred to as immunomodulatory drugs and seem to reverse leukemia-induced\nimmunosuppression, but in addition, they have direct inhibitory effects on the AML cells. The\ncombination of checkpoint targeting and thalidomide derivatives thus represents a strategy for\ndual immunotargeting together with a direct antileukemic effect.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Checkpoint inhibitors are now tried in AML. Experimental studies suggest that\nthese inhibitors should be combined with immunomodulatory agents (i.e. thalidomide derivatives)\nand\/or new targeted or conventional antileukemic treatment. Such combinations would\nallow dual immunotargeting (checkpoint inhibitor, immunomodulatory agents) together with\na double\/triple direct targeting of the leukemic cells.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666190325095853","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T10:36:14Z","timestamp":1553510174000},"page":"5244-5261","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments"],"prefix":"10.2174","volume":"26","author":[{"given":"Eva","family":"Leufven","sequence":"first","affiliation":[{"name":"Department of Clinical Science, University of Bergen, Jonas Lies vei 87, N-5020 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8ystein","family":"Bruserud","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, Jonas Lies vei 87, N-5020 Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1586\/ehm.11.54","volume":"4","author":"Melve G.K.","year":"2011","unstructured":"Melve G.K.; Ersvssr E.; Kittang A.O.; Bruserud O.; The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target? Expert Rev Hematol 2011,4(5),563-576","journal-title":"Expert Rev Hematol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.leukres.2017.06.011","volume":"60","author":"Blum S.","year":"2017","unstructured":"Blum S.; Martins F.; L\u00fcbbert M.; Immunotherapy in adult acute leukemia. Leuk Res 2017,60,63-73","journal-title":"Leuk Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1389450116666150518095346","volume":"18","author":"Knaus H.A.","year":"2017","unstructured":"Knaus H.A.; Kanakry C.G.; Luznik L.; Gojo I.; Immunomodulatory drugs: Immune checkpoint agents in acute leukemia. Curr Drug Targets 2017,18(3),315-331","journal-title":"Curr Drug Targets"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-319-53156-4_4","volume":"995","author":"Masarova L.","year":"2017","unstructured":"Masarova L.; Kantarjian H.; Garcia-Mannero G.; Ravandi F.; Sharma P.; Daver N.; Harnessing the immune system against leukemia: Monoclonal antibodies and checkpoint strategies for AML. Adv Exp Med Biol 2017,995,73-95","journal-title":"Adv Exp Med Biol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1146\/annurev.immunol.21.120601.141135","volume":"21","author":"Pardoll D.","year":"2003","unstructured":"Pardoll D.; Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003,21,807-839","journal-title":"Annu Rev Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"Yee C.","year":"2002","unstructured":"Yee C.; Thompson J.A.; Byrd D.; Riddell S.R.; Roche P.; Celis E.; Greenberg P.D.; Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002,99(25),16168-16173","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00008390-199708000-00006","volume":"7","author":"Moretti S.","year":"1997","unstructured":"Moretti S.; Pinzi C.; Berti E.; Spallanzani A.; Chiarugi A.; Boddi V.; Reali U.M.; Giannotti B.; In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 1997,7(4),313-321","journal-title":"Melanoma Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/eji.1830261119","volume":"26","author":"Bogen B.","year":"1996","unstructured":"Bogen B.; Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996,26(11),2671-2679","journal-title":"Eur J Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2174\/138945011798184146","volume":"12","author":"Lollini P.L.","year":"2011","unstructured":"Lollini P.L.; Nicoletti G.; Landuzzi L.; Cavallo F.; Forni G.; De Giovanni C.; Nanni P.; Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets 2011,12(13),1957-1973","journal-title":"Curr Drug Targets"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/1078-0432.CCR-14-1186","volume":"21","author":"Chu N.J.","year":"2015","unstructured":"Chu N.J.; Armstrong T.D.; Jaffee E.M.; Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res 2015,21(7),1549-1557","journal-title":"Clin Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"Wherry E.J.","year":"2011","unstructured":"Wherry E.J.; T cell exhaustion. Nat Immunol 2011,12(6),492-499","journal-title":"Nat Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","volume":"8","author":"Schnorfeil F.M.","year":"2015","unstructured":"Schnorfeil F.M.; Lichtenegger F.S.; Emmerig K.; Schlueter M.; Neitz J.S.; Draenert R.; Hiddemann W.; Subklewe M.; T cells are functionally not impaired in AML: Increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol 2015,8,93","journal-title":"J Hematol Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","volume":"29","author":"Tan J.","year":"2017","unstructured":"Tan J.; Chen S.; Lu Y.; Yao D.; Xu L.; Zhang Y.; Yang L.; Chen J.; Lai J.; Yu Z.; Zhu K.; Li Y.; Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia. Chin J Cancer Res 2017,29(5),463-470","journal-title":"Chin J Cancer Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1179\/102453308X343491","volume":"13","author":"Olsnes A.M.","year":"2008","unstructured":"Olsnes A.M.; Ersvaer E.; Ryningen A.; Bruserud O.; Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors. Hematology 2008,13(6),329-332","journal-title":"Hematology"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2172-11-38","volume":"11","author":"Ersvaer E.","year":"2010","unstructured":"Ersvaer E.; Liseth K.; Skavland J.; Gjertsen B.T.; Bruserud \u00d8.; Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 2010,11,38","journal-title":"BMC Immunol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","volume":"190","author":"Wang M.","year":"2018","unstructured":"Wang M.; Bu J.; Zhou M.; Sido J.; Lin Y.; Liu G.; Lin Q.; Xu X.; Leavenworth J.W.; Shen E.; CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol 2018,190,64-73","journal-title":"Clin Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"Yu X.","year":"2009","unstructured":"Yu X.; Harden K.; Gonzalez L.C.; Francesco M.; Chiang E.; Irving B.; Tom I.; Ivelja S.; Refino C.J.; Clark H.; Eaton D.; Grogan J.L.; The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009,10(1),48-57","journal-title":"Nat Immunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1600-0609.1997.tb01686.x","volume":"59","author":"Bruserud O.","year":"1997","unstructured":"Bruserud O.; Ulvestad E.; Halstensen A.; Berentsen S.; Bergheim J.; Nesthus I.; Interleukin 4 responses in acute leukaemia patients with severe chemotherapy-induced leucopenia. Eur J Haematol 1997,59(5),269-276","journal-title":"Eur J Haematol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s002620050399","volume":"45","author":"Bruserud O.","year":"1997","unstructured":"Bruserud O.; Pawelec G.; Interleukin-13 secretion by normal and posttransplant T lymphocytes; in vitro studies of cellular immune responses in the presence of acute leukaemia blast cells. Cancer Immunol Immunother 1997,45(1),45-52","journal-title":"Cancer Immunol Immunother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000039756","volume":"104","author":"Bruserud O.","year":"2000","unstructured":"Bruserud O.; von Volkman H.L.; Ulvestad E.; The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: characterization of T lymphocyte subsets responsive to IL-16 and IL-17. Acta Haematol 2000,104(2-3),80-91","journal-title":"Acta Haematol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1089\/10799900050198381","volume":"20","author":"Bruserud O.","year":"2000","unstructured":"Bruserud O.; Ulvestad E.; Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia. J Interferon Cytokine Res 2000,20(11),947-954","journal-title":"J Interferon Cytokine Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1365-3083.1998.00254.x","volume":"47","author":"Bruserud O.","year":"1998","unstructured":"Bruserud O.; Ulvestad E.; Berentsen S.; Bergheim J.; Nesthus I.; T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation. Scand J Immunol 1998,47(1),54-62","journal-title":"Scand J Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1006\/cimm.2000.1725","volume":"206","author":"Bruserud O.","year":"2000","unstructured":"Bruserud O.; Ulvestad E.; Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation. Cell Immunol 2000,206(1),36-50","journal-title":"Cell Immunol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1634\/stemcells.18-1-10","volume":"18","author":"Mackall C.L.","year":"2000","unstructured":"Mackall C.L.; T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review. Stem Cells 2000,18(1),10-18","journal-title":"Stem Cells"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12967-017-1252-2","volume":"15","author":"Goswami M.","year":"2017","unstructured":"Goswami M.; Prince G.; Biancotto A.; Moir S.; Kardava L.; Santich B.H.; Cheung F.; Kotliarov Y.; Chen J.; Shi R.; Zhou H.; Golding H.; Manischewitz J.; King L.; Kunz L.M.; Noonan K.; Borrello I.M.; Smith B.D.; Hourigan C.S.; Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. J Transl Med 2017,15(1),155","journal-title":"J Transl Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1868-7083-5-13","volume":"5","author":"Fredly H.","year":"2013","unstructured":"Fredly H.; Ersv\u00e6r E.; Kittang A.O.; Tsykunova G.; Gjertsen B.T.; Bruserud O.; The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics 2013,5(1),13","journal-title":"Clin Epigenetics"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbmt.2011.08.007","volume":"18","author":"Thoma M.D.","year":"2012","unstructured":"Thoma M.D.; Huneke T.J.; DeCook L.J.; Johnson N.D.; Wiegand R.A.; Litzow M.R.; Hogan W.J.; Porrata L.F.; Holtan S.G.; Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 2012,18(4),600-607","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.leu.2404032","volume":"20","author":"Behl D.","year":"2006","unstructured":"Behl D.; Porrata L.F.; Markovic S.N.; Letendre L.; Pruthi R.K.; Hook C.C.; Tefferi A.; Elliot M.A.; Kaufmann S.H.; Mesa R.A.; Litzow M.R.; Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006,20(1),29-34","journal-title":"Leukemia"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/sj.leu.2402503","volume":"16","author":"Porrata L.F.","year":"2002","unstructured":"Porrata L.F.; Litzow M.R.; Tefferi A.; Letendre L.; Kumar S.; Geyer S.M.; Markovic S.N.; Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002,16(7),1311-1318","journal-title":"Leukemia"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"D\u00f6hner H.","year":"2017","unstructured":"D\u00f6hner H.; Estey E.; Grimwade D.; Amadori S.; Appelbaum F.R.; B\u00fcchner T.; Dombret H.; Ebert B.L.; Fenaux P.; Larson R.A.; Levine R.L.; Lo-Coco F.; Naoe T.; Niederwieser D.; Ossenkoppele G.J.; Sanz M.; Sierra J.; Tallman M.S.; Tien H.F.; Wei A.H.; L\u00f6wenberg B.; Bloomfield C.D.; Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017,129(4),424-447","journal-title":"Blood"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","volume":"9","author":"Cornelissen J.J.","year":"2012","unstructured":"Cornelissen J.J.; Gratwohl A.; Schlenk R.F.; Sierra J.; Bornh\u00e4user M.; Juliusson G.; R\u00e5cil Z.; Rowe J.M.; Russell N.; Mohty M.; L\u00f6wenberg B.; Soci\u00e9 G.; Niederwieser D.; Ossenkoppele G.J.; The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012,9(10),579-590","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.blre.2016.09.005","volume":"31","author":"Podoltsev N.A.","year":"2017","unstructured":"Podoltsev N.A.; Stahl M.; Zeidan A.M.; Gore S.D.; Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev 2017,31(2),43-62","journal-title":"Blood Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","volume":"18","author":"Bose P.","year":"2017","unstructured":"Bose P.; Vachhani P.; Cortes J.E.; Treatment of relapsed\/refractory acute myeloid leukemia. Curr Treat Options Oncol 2017,18(3),17","journal-title":"Curr Treat Options Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1868-7083-5-12","volume":"5","author":"Fredly H.","year":"2013","unstructured":"Fredly H.; Gjertsen B.T.; Bruserud O.; Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics 2013,5(1),12","journal-title":"Clin Epigenetics"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1002\/jcph.990","volume":"57","author":"Sheng J.","year":"2017","unstructured":"Sheng J.; Srivastava S.; Sanghavi K.; Lu Z.; Schmidt B.J.; Bello A.; Gupta M.; Clinical pharmacology considerations for the development of immune checkpoint inhibitors. J Clin Pharmacol 2017,57(Suppl. 10),S26-S42","journal-title":"J Clin Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3747\/co.25.4235","volume":"25","author":"Myers G.","year":"2018","unstructured":"Myers G.; Immune-related adverse events of immune checkpoint inhibitors: A brief review. Curr Oncol 2018,25(5),342-347","journal-title":"Curr Oncol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"Kumar V.","year":"2017","unstructured":"Kumar V.; Chaudhary N.; Garg M.; Floudas C.S.; Soni P.; Chandra A.B.; Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017,8,49","journal-title":"Front Pharmacol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","volume":"73","author":"El Majzoub I.","year":"2019","unstructured":"El Majzoub I.; Qdaisat A.; Thein K.Z.; Win M.A.; Han M.M.; Jacobson K.; Chaftari P.S.; Prejean M.; Reyes-Gibby C.; Yeung S.J.; Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med 2019,73(1),79-87","journal-title":"Ann Emerg Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","volume":"10","author":"Ok C.Y.","year":"2017","unstructured":"Ok C.Y.; Young K.H.; Checkpoint inhibitors in hematological malignancies. J Hematol Oncol 2017,10(1),103","journal-title":"J Hematol Oncol"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","volume":"59","author":"Boddu P.","year":"2018","unstructured":"Boddu P.; Kantarjian H.; Garcia-Manero G.; Allison J.; Sharma P.; Daver N.; The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 2018,59(4),790-802","journal-title":"Leuk Lymphoma"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","volume":"229","author":"Rudd C.E.","year":"2009","unstructured":"Rudd C.E.; Taylor A.; Schneider H.; CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009,229(1),12-26","journal-title":"Immunol Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"Tivol E.A.","year":"1995","unstructured":"Tivol E.A.; Borriello F.; Schweitzer A.N.; Lynch W.P.; Bluestone J.A.; Sharpe A.H.; Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995,3(5),541-547","journal-title":"Immunity"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/14712598.2016.1152256","volume":"16","author":"Ryan J.M.","year":"2016","unstructured":"Ryan J.M.; Wasser J.S.; Adler A.J.; Vella A.T.; Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther 2016,16(5),655-674","journal-title":"Expert Opin Biol Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"Hodi F.S.","year":"2010","unstructured":"Hodi F.S.; O\u2019Day S.J.; McDermott D.F.; Weber R.W.; Sosman J.A.; Haanen J.B.; Gonzalez R.; Robert C.; Schadendorf D.; Hassel J.C.; Akerley W.; van den Eertwegh A.J.; Lutzky J.; Lorigan P.; Vaubel J.M.; Linette G.P.; Hogg D.; Ottensmeier C.H.; Lebb\u00e9 C.; Peschel C.; Quirt I.; Clark J.I.; Wolchok J.D.; Weber J.S.; Tian J.; Yellin M.J.; Nichol G.M.; Hoos A.; Urba W.J.; Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010,363(8),711-723","journal-title":"N Engl J Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/leu.2008.339","volume":"23","author":"P\u00e9rez-Garc\u00eda A.","year":"2009","unstructured":"P\u00e9rez-Garc\u00eda A.; Brunet S.; Berlanga J.J.; Tormo M.; Nomdedeu J.; Guardia R.; Ribera J.M.; Heras I.; Llorente A.; Hoyos M.; Esteve J.; Besalduch J.; Bueno J.; Sierra J.; Gallardo D.; CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 2009,23(3),486-491","journal-title":"Leukemia"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00262-016-1815-8","volume":"65","author":"Poh S.L.","year":"2016","unstructured":"Poh S.L.; Linn Y.C.; Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. Cancer Immunol Immunother 2016,65(5),525-536","journal-title":"Cancer Immunol Immunother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00262-017-2040-9","volume":"66","author":"Sander F.E.","year":"2017","unstructured":"Sander F.E.; Nilsson M.; Rydstr\u00f6m A.; Aurelius J.; Riise R.E.; Movitz C.; Bernson E.; Kiffin R.; St\u00e5hlberg A.; Brune M.; Fo\u00e0 R.; Hellstrand K.; Thor\u00e9n F.B.; Martner A.; Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. Cancer Immunol Immunother 2017,66(11),1473-1484","journal-title":"Cancer Immunol Immunother"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/14653240500499507","volume":"8","author":"Zhong R.K.","year":"2006","unstructured":"Zhong R.K.; Loken M.; Lane T.A.; Ball E.D.; CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Cytotherapy 2006,8(1),3-12","journal-title":"Cytotherapy"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/jir.2007.0052","volume":"28","author":"Olsnes A.M.","year":"2008","unstructured":"Olsnes A.M.; Ryningen A.; Ersvaer E.; Bruserud \u00d8.; \n                        In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. J Interferon Cytokine Res 2008,28(5),297-310","journal-title":"J Interferon Cytokine Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2002-06-1668","volume":"101","author":"Pistillo M.P.","year":"2003","unstructured":"Pistillo M.P.; Tazzari P.L.; Palmisano G.L.; Pierri I.; Bolognesi A.; Ferlito F.; Capanni P.; Polito L.; Ratta M.; Pileri S.; Piccioli M.; Basso G.; Rissotto L.; Conte R.; Gobbi M.; Stirpe F.; Ferrara G.B.; CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003,101(1),202-209","journal-title":"Blood"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2141.2006.06472.x","volume":"136","author":"Laurent S.","year":"2007","unstructured":"Laurent S.; Palmisano G.L.; Martelli A.M.; Kato T.; Tazzari P.L.; Pierri I.; Clavio M.; Dozin B.; Balbi G.; Megna M.; Morabito A.; Lamparelli T.; Bacigalupo A.; Gobbi M.; Pistillo M.P.; CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. Br J Haematol 2007,136(4),597-608","journal-title":"Br J Haematol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.bbmt.2014.03.005","volume":"20","author":"Sengsayadeth S.","year":"2014","unstructured":"Sengsayadeth S.; Wang T.; Lee S.J.; Haagenson M.D.; Spellman S.; Fernandez Vi\u00f1a M.A.; Muller C.R.; Verneris M.R.; Savani B.N.; Jagasia M.; Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant 2014,20(6),900-903","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"Freeman G.J.","year":"2000","unstructured":"Freeman G.J.; Long A.J.; Iwai Y.; Bourque K.; Chernova T.; Nishimura H.; Fitz L.J.; Malenkovich N.; Okazaki T.; Byrne M.C.; Horton H.F.; Fouser L.; Carter L.; Ling V.; Bowman M.R.; Carreno B.M.; Collins M.; Wood C.R.; Honjo T.; Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000,192(7),1027-1034","journal-title":"J Exp Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","volume":"116","author":"Zhou Q.","year":"2010","unstructured":"Zhou Q.; Munger M.E.; Highfill S.L.; Tolar J.; Weigel B.J.; Riddle M.; Sharpe A.H.; Vallera D.A.; Azuma M.; Levine B.L.; June C.H.; Murphy W.J.; Munn D.H.; Blazar B.R.; Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2010,116(14),2484-2493","journal-title":"Blood"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","volume":"114","author":"Zhang L.","year":"2009","unstructured":"Zhang L.; Gajewski T.F.; Kline J.; PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009,114(8),1545-1552","journal-title":"Blood"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Zhou Q.","year":"2011","unstructured":"Zhou Q.; Munger M.E.; Veenstra R.G.; Weigel B.J.; Hirashima M.; Munn D.H.; Murphy W.J.; Azuma M.; Anderson A.C.; Kuchroo V.K.; Blazar B.R.; Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011,117(17),4501-4510","journal-title":"Blood"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/ejh.12762","volume":"97","author":"Schmohl J.U.","year":"2016","unstructured":"Schmohl J.U.; Nuebling T.; Wild J.; Kroell T.; Kanz L.; Salih H.R.; Schmetzer H.; Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis. Eur J Haematol 2016,97(6),517-527","journal-title":"Eur J Haematol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1038\/leu.2017.163","volume":"31","author":"Pyzer A.R.","year":"2017","unstructured":"Pyzer A.R.; Stroopinsky D.; Rosenblatt J.; Anastasiadou E.; Rajabi H.; Washington A.; Tagde A.; Chu J.H.; Coll M.; Jiao A.L.; Tsai L.T.; Tenen D.E.; Cole L.; Palmer K.; Ephraim A.; Leaf R.K.; Nahas M.; Apel A.; Bar-Natan M.; Jain S.; McMasters M.; Mendez L.; Arnason J.; Raby B.A.; Slack F.; Kufe D.; Avigan D.; MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia 2017,31(12),2780-2790","journal-title":"Leukemia"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1257454","volume":"6","author":"Goltz D.","year":"2016","unstructured":"Goltz D.; Gevensleben H.; Dietrich J.; Dietrich D.; \n                        PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. OncoImmunology 2016,6(1)","journal-title":"OncoImmunology"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.18632\/oncotarget.3324","volume":"6","author":"\u00d8rskov A.D.","year":"2015","unstructured":"\u00d8rskov A.D.; Treppendahl M.B.; Skovbo A.; Holm M.S.; Friis L.S.; Hokland M.; Gr\u00f8nb\u00e6k K.; Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015,6(11),9612-9626","journal-title":"Oncotarget"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"Yang H.","year":"2014","unstructured":"Yang H.; Bueso-Ramos C.; DiNardo C.; Estecio M.R.; Davanlou M.; Geng Q.R.; Fang Z.; Nguyen M.; Pierce S.; Wei Y.; Parmar S.; Cortes J.; Kantarjian H.; Garcia-Manero G.; Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014,28(6),1280-1288","journal-title":"Leukemia"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"Krupka C.","year":"2016","unstructured":"Krupka C.; Kufer P.; Kischel R.; Zugmaier G.; Lichtenegger F.S.; K\u00f6hnke T.; Vick B.; Jeremias I.; Metzeler K.H.; Altmann T.; Schneider S.; Fiegl M.; Spiekermann K.; Bauerle P.A.; Hiddemann W.; Riethm\u00fcller G.; Subklewe M.; Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: Reversing a T-cell-induced immune escape mechanism. Leukemia 2016,30(2),484-491","journal-title":"Leukemia"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.58","volume":"5","author":"Kong Y.","year":"2015","unstructured":"Kong Y.; Zhang J.; Claxton D.F.; Ehmann W.C.; Rybka W.B.; Zhu L.; Zeng H.; Schell T.D.; Zheng H.; PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J 2015,5","journal-title":"Blood Cancer J"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834014567470","volume":"7","author":"Sundar R.","year":"2015","unstructured":"Sundar R.; Cho B.C.; Brahmer J.R.; Soo R.A.; Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 2015,7(2),85-96","journal-title":"Ther Adv Med Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"Curran M.A.","year":"2010","unstructured":"Curran M.A.; Montalvo W.; Yagita H.; Allison J.P.; PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010,107(9),4275-4280","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ejh.12228","volume":"92","author":"Kr\u00f6nig H.","year":"2014","unstructured":"Kr\u00f6nig H.; Kremmler L.; Haller B.; Englert C.; Peschel C.; Andreesen R.; Blank C.U.; Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol 2014,92(3),195-203","journal-title":"Eur J Haematol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"Dong H.","year":"2002","unstructured":"Dong H.; Strome S.E.; Salomao D.R.; Tamura H.; Hirano F.; Flies D.B.; Roche P.C.; Lu J.; Zhu G.; Tamada K.; Lennon V.A.; Celis E.; Chen L.; Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002,8(8),793-800","journal-title":"Nat Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","volume":"7","author":"Chen X.","year":"2008","unstructured":"Chen X.; Liu S.; Wang L.; Zhang W.; Ji Y.; Ma X.; Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther 2008,7(5),622-627","journal-title":"Cancer Biol Ther"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2013-01-480129","volume":"122","author":"Mussai F.","year":"2013","unstructured":"Mussai F.; De Santo C.; Abu-Dayyeh I.; Booth S.; Quek L.; McEwen-Smith R.M.; Qureshi A.; Dazzi F.; Vyas P.; Cerundolo V.; Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 2013,122(5),749-758","journal-title":"Blood"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1074\/jbc.M116.769422","volume":"292","author":"Samuchiwal S.K.","year":"2017","unstructured":"Samuchiwal S.K.; Balestrieri B.; Raff H.; Boyce J.A.; Endogenous prostaglandin E amplifies IL-33 production by macrophages through an E prostanoid (EP)\/EP-cAMP-EPAC-dependent pathway. J Biol Chem 2017,292(20),8195-8206","journal-title":"J Biol Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.3892\/mmr.2015.4176","volume":"12","author":"Zeng K.","year":"2015","unstructured":"Zeng K.; Deng B.P.; Jiang H.Q.; Wang M.; Hua P.; Zhang H.W.; Deng Y.B.; Yang Y.Q.; Prostaglandin E.; Prostaglandin E protects bone marrow-derived mesenchymal stem cells against serum deprivation-induced apoptosis. Mol Med Rep 2015,12(4),5723-5729","journal-title":"Mol Med Rep"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.3390\/molecules180910132","volume":"18","author":"Iachininoto M.G.","year":"2013","unstructured":"Iachininoto M.G.; Nuzzolo E.R.; Bonanno G.; Mariotti A.; Procoli A.; Locatelli F.; De Cristofaro R.; Rutella S.; Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells. Molecules 2013,18(9),10132-10145","journal-title":"Molecules"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-014-0278-9","volume":"14","author":"Naderi E.H.","year":"2015","unstructured":"Naderi E.H.; Skah S.; Ugland H.; Myklebost O.; Sandnes D.L.; Torgersen M.L.; Josefsen D.; Ruud E.; Naderi S.; Blomhoff H.K.; Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death. Mol Cancer 2015,14,14","journal-title":"Mol Cancer"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.4049\/jimmunol.176.11.6752","volume":"176","author":"Fallarino F.","year":"2006","unstructured":"Fallarino F.; Grohmann U.; You S.; McGrath B.C.; Cavener D.R.; Vacca C.; Orabona C.; Bianchi R.; Belladonna M.L.; Volpi C.; Santamaria P.; Fioretti M.C.; Puccetti P.; The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006,176(11),6752-6761","journal-title":"J Immunol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","volume":"109","author":"Curti A.","year":"2007","unstructured":"Curti A.; Pandolfi S.; Valzasina B.; Aluigi M.; Isidori A.; Ferri E.; Salvestrini V.; Bonanno G.; Rutella S.; Durelli I.; Horenstein A.L.; Fiore F.; Massaia M.; Colombo M.P.; Baccarani M.; Lemoli R.M.; Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007,109(7),2871-2877","journal-title":"Blood"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3389\/fimmu.2017.01360","volume":"8","author":"Mellor A.L.","year":"2017","unstructured":"Mellor A.L.; Lemos H.; Huang L.; Indoleamine 2,3-dioxygenase and tolerance: Where are we now? Front Immunol 2017,8,1360","journal-title":"Front Immunol"},{"key":"ref=77","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/636292","volume":"2014","author":"Locafaro G.","year":"2014","unstructured":"Locafaro G.; Amodio G.; Tomasoni D.; Tresoldi C.; Ciceri F.; Gregori S.; HLA-G expression on blasts and tolerogenic cells in patients affected by acute myeloid leukemia. J Immunol Res 2014,2014","journal-title":"J Immunol Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","volume":"15","author":"Szczepanski M.J.","year":"2009","unstructured":"Szczepanski M.J.; Szajnik M.; Czystowska M.; Mandapathil M.; Strauss L.; Welsh A.; Foon K.A.; Whiteside T.L.; Boyiadzis M.; Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009,15(10),3325-3332","journal-title":"Clin Cancer Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","volume":"118","author":"Ustun C.","year":"2011","unstructured":"Ustun C.; Miller J.S.; Munn D.H.; Weisdorf D.J.; Blazar B.R.; Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011,118(19),5084-5095","journal-title":"Blood"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1517\/14712598.2014.927432","volume":"14","author":"Whiteside T.L.","year":"2014","unstructured":"Whiteside T.L.; Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther 2014,14(10),1411-1425","journal-title":"Expert Opin Biol Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/14728222.2017.1300255","volume":"21","author":"Brenner A.K.","year":"2017","unstructured":"Brenner A.K.; Tvedt T.H.; Nepstad I.; Rye K.P.; Hagen K.M.; Reikvam H.; Bruserud \u00d8.; Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. Expert Opin Ther Targets 2017,21(4),357-369","journal-title":"Expert Opin Ther Targets"},{"key":"ref=82","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1062208","volume":"5","author":"Kittang A.O.","year":"2015","unstructured":"Kittang A.O.; Kordasti S.; Sand K.E.; Costantini B.; Kramer A.M.; Perezabellan P.; Seidl T.; Rye K.P.; Hagen K.M.; Kulasekararaj A.; Bruserud \u00d8.; Mufti G.J.; Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. OncoImmunology 2015,5(2)","journal-title":"OncoImmunology"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3324\/haematol.10148","volume":"92","author":"Bruserud \u00d8.","year":"2007","unstructured":"Bruserud \u00d8.; Ryningen A.; Olsnes A.M.; Stordrange L.; \u00d8yan A.M.; Kalland K.H.; Gjertsen B.T.; Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007,92(3),332-341","journal-title":"Haematologica"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00432-017-2458-7","volume":"143","author":"Honnemyr M.","year":"2017","unstructured":"Honnemyr M.; Bruserud \u00d8.; Brenner A.K.; The constitutive protease release by primary human acute myeloid leukemia cells. J Cancer Res Clin Oncol 2017,143(10),1985-1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"Biswas S.K.","year":"2010","unstructured":"Biswas S.K.; Mantovani A.; Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010,11(10),889-896","journal-title":"Nat Immunol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.smim.2018.01.002","volume":"35","author":"Cheung T.S.","year":"2018","unstructured":"Cheung T.S.; Dazzi F.; Mesenchymal-myeloid interaction in the regulation of immunity. Semin Immunol 2018,35,59-68","journal-title":"Semin Immunol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/ni.3002","volume":"15","author":"Wang Y.","year":"2014","unstructured":"Wang Y.; Chen X.; Cao W.; Shi Y.; Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nat Immunol 2014,15(11),1009-1016","journal-title":"Nat Immunol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.autrev.2017.07.008","volume":"16","author":"Al-Soudi A.","year":"2017","unstructured":"Al-Soudi A.; Kaaij M.H.; Tas S.W.; Endothelial cells: From innocent bystanders to active participants in immune responses. Autoimmun Rev 2017,16(9),951-962","journal-title":"Autoimmun Rev"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3389\/fimmu.2016.00480","volume":"7","author":"Navarro R.","year":"2016","unstructured":"Navarro R.; Compte M.; \u00c1lvarez-Vallina L.; Sanz L.; Immune regulation by pericytes: Modulating innate and adaptive immunity. Front Immunol 2016,7,480","journal-title":"Front Immunol"},{"key":"ref=90","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21111512","volume":"21","author":"Brenner A.K.","year":"2016","unstructured":"Brenner A.K.; Andersson Tvedt T.H.; Bruserud \u00d8.; The complexity of targeting PI3K-Akt-mTOR signalling in human acute myeloid leukaemia: The importance of leukemic cell heterogeneity, neighbouring mesenchymal stem cells and immunocompetent cells. Molecules 2016,21(11)","journal-title":"Molecules"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1517\/14712598.2015.1051028","volume":"15","author":"Sehgal A.","year":"2015","unstructured":"Sehgal A.; Whiteside T.L.; Boyiadzis M.; Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin Biol Ther 2015,15(8),1191-1203","journal-title":"Expert Opin Biol Ther"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1365-2141.2002.03247.x","volume":"116","author":"Linn Y.C.","year":"2002","unstructured":"Linn Y.C.; Lau L.C.; Hui K.M.; Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002,116(1),78-86","journal-title":"Br J Haematol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1002\/eji.201444500","volume":"44","author":"Khaznadar Z.","year":"2014","unstructured":"Khaznadar Z.; Henry G.; Setterblad N.; Agaugue S.; Raffoux E.; Boissel N.; Dombret H.; Toubert A.; Dulphy N.; Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. Eur J Immunol 2014,44(10),3068-3080","journal-title":"Eur J Immunol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/13543784.2017.1313230","volume":"26","author":"Itchaki G.","year":"2017","unstructured":"Itchaki G.; Brown J.R.; Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs 2017,26(5),633-650","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1080\/14656566.2017.1409207","volume":"18","author":"Richardson P.G.","year":"2017","unstructured":"Richardson P.G.; Holstein S.A.; Schlossman R.L.; Anderson K.C.; Attal M.; McCarthy P.L.; Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: A review of options for and against. Expert Opin Pharmacother 2017,18(18),1975-1985","journal-title":"Expert Opin Pharmacother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/1389450116666150304104315","volume":"18","author":"Zeidner J.F.","year":"2017","unstructured":"Zeidner J.F.; Foster M.C.; Immunomodulatory drugs: IMiDs in Acute Myeloid Leukemia (AML). Curr Drug Targets 2017,18(3),304-314","journal-title":"Curr Drug Targets"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1517\/13543784.2013.758712","volume":"22","author":"Chen Y.","year":"2013","unstructured":"Chen Y.; Borthakur G.; Lenalidomide as a novel treatment of acute myeloid leukemia. Expert Opin Investig Drugs 2013,22(3),389-397","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CMAR.S81310","volume":"7","author":"Ghosh N.","year":"2015","unstructured":"Ghosh N.; Grunwald M.R.; Fasan O.; Bhutani M.; Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res 2015,7,105-119","journal-title":"Cancer Manag Res"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1200\/JCO.2010.30.3339","volume":"28","author":"Blum W.","year":"2010","unstructured":"Blum W.; Klisovic R.B.; Becker H.; Yang X.; Rozewski D.M.; Phelps M.A.; Garzon R.; Walker A.; Chandler J.C.; Whitman S.P.; Curfman J.; Liu S.; Schaaf L.; Mickle J.; Kefauver C.; Devine S.M.; Grever M.R.; Marcucci G.; Byrd J.C.; Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010,28(33),4919-4925","journal-title":"J Clin Oncol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1182\/blood-2008-04-152678","volume":"113","author":"Fehniger T.A.","year":"2009","unstructured":"Fehniger T.A.; Byrd J.C.; Marcucci G.; Abboud C.N.; Kefauver C.; Payton J.E.; Vij R.; Blum W.; Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009,113(5),1002-1005","journal-title":"Blood"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1182\/blood-2010-07-297143","volume":"117","author":"Fehniger T.A.","year":"2011","unstructured":"Fehniger T.A.; Uy G.L.; Trinkaus K.; Nelson A.D.; Demland J.; Abboud C.N.; Cashen A.F.; Stockerl-Goldstein K.E.; Westervelt P.; DiPersio J.F.; Vij R.; A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011,117(6),1828-1833","journal-title":"Blood"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.clml.2012.04.001","volume":"12","author":"Chen Y.","year":"2012","unstructured":"Chen Y.; Kantarjian H.; Estrov Z.; Faderl S.; Ravandi F.; Rey K.; Cortes J.; Borthakur G.; A phase II study of lenalidomide alone in relapsed\/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk 2012,12(5),341-344","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3324\/haematol.2017.172353","volume":"103","author":"Medeiros B.C.","year":"2018","unstructured":"Medeiros B.C.; McCaul K.; Kambhampati S.; Pollyea D.A.; Kumar R.; Silverman L.R.; Kew A.; Saini L.; Beach C.L.; Vij R.; Wang X.; Zhong J.; Gale R.P.; Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. Haematologica 2018,103(1),101-106","journal-title":"Haematologica"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(14)00026-X","volume":"2","author":"DiNardo C.D.","year":"2015","unstructured":"DiNardo C.D.; Daver N.; Jabbour E.; Kadia T.; Borthakur G.; Konopleva M.; Pemmaraju N.; Yang H.; Pierce S.; Wierda W.; Bueso-Ramos C.; Patel K.P.; Cortes J.E.; Ravandi F.; Kantarjian H.M.; Garcia-Manero G.; Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1\/2 study. Lancet Haematol 2015,2(1),e12-e20","journal-title":"Lancet Haematol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.leukres.2017.09.019","volume":"62","author":"Visani G.","year":"2017","unstructured":"Visani G.; Ferrara F.; Di Raimondo F.; Loscocco F.; Fuligni F.; Paolini S.; Zammit V.; Spina E.; Rocchi M.; Visani A.; Piccaluga P.P.; Isidori A.; Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. Leuk Res 2017,62,77-83","journal-title":"Leuk Res"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.leukres.2016.02.003","volume":"43","author":"Griffiths E.A.","year":"2016","unstructured":"Griffiths E.A.; Brady W.E.; Tan W.; Vigil C.E.; Thompson J.E.; Ford L.A.; Dickey N.M.; L Bashaw.; H.; Sperrazza, J.; Wetzler, M.; Wang, E.S. A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed\/refractory acute myeloid leukemia. Leuk Res 2016,43,44-48","journal-title":"Leuk Res"},{"key":"ref=107","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.50","volume":"7","author":"Hunault-Berger M.","year":"2017","unstructured":"Hunault-Berger M.; Maillard N.; Himberlin C.; Recher C.; Schmidt-Tanguy A.; Choufi B.; Bonmati C.; Carr\u00e9 M.; Couturier M.A.; Daguindau E.; Marolleau J.P.; Orsini-Piocelle F.; Delaunay J.; Tavernier E.; Lissandre S.; Ojeda-Uribe M.; Sanhes L.; Sutton L.; Banos A.; Fornecker L.M.; Bernard M.; Bouscary D.; Saad A.; Puyade M.; Rouill\u00e9 V.; Luquet I.; B\u00e9n\u00e9 M.C.; Hamel J.F.; Dreyfus F.; Ifrah N.; Pigneux A.; Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial. Blood Cancer J 2017,7(6)","journal-title":"Blood Cancer J"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3324\/haematol.2016.151894","volume":"102","author":"Ades L.","year":"2017","unstructured":"Ades L.; Prebet T.; Stamatoullas A.; Recher C.; Guieze R.; Raffoux E.; Bouabdallah K.; Hunault M.; Wattel E.; Stalnikiewicz L.; Toma A.; Dombret H.; Vey N.; Sebert M.; Gardin C.; Chaffaut C.; Chevret S.; Fenaux P.; Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des My\u00e9lodysplasies. Haematologica 2017,102(4),728-735","journal-title":"Haematologica"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2174\/1568009616666160408145741","volume":"16","author":"Riches J.C.","year":"2016","unstructured":"Riches J.C.; Gribben J.G.; Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia. Curr Cancer Drug Targets 2016,16(8),689-700","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","volume":"26","author":"Andritsos L.A.","year":"2008","unstructured":"Andritsos L.A.; Johnson A.J.; Lozanski G.; Blum W.; Kefauver C.; Awan F.; Smith L.L.; Lapalombella R.; May S.E.; Raymond C.A.; Wang D.S.; Knight R.D.; Ruppert A.S.; Lehman A.; Jarjoura D.; Chen C.S.; Byrd J.C.; Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008,26(15),2519-2525","journal-title":"J Clin Oncol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2014-03-559591","volume":"124","author":"Fecteau J.F.","year":"2014","unstructured":"Fecteau J.F.; Corral L.G.; Ghia E.M.; Gaidarova S.; Futalan D.; Bharati I.S.; Cathers B.; Schwaederl\u00e9 M.; Cui B.; Lopez-Girona A.; Messmer D.; Kipps T.J.; Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21(WAF1\/Cip1)-dependent mechanism independent of functional p53. Blood 2014,124(10),1637-1644","journal-title":"Blood"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"Lopez-Girona A.","year":"2012","unstructured":"Lopez-Girona A.; Mendy D.; Ito T.; Miller K.; Gandhi A.K.; Kang J.; Karasawa S.; Carmel G.; Jackson P.; Abbasian M.; Mahmoudi A.; Cathers B.; Rychak E.; Gaidarova S.; Chen R.; Schafer P.H.; Handa H.; Daniel T.O.; Evans J.F.; Chopra R.; Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012,26(11),2326-2335","journal-title":"Leukemia"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","volume":"116","author":"G\u00f6rg\u00fcn G.","year":"2010","unstructured":"G\u00f6rg\u00fcn G.; Calabrese E.; Soydan E.; Hideshima T.; Perrone G.; Bandi M.; Cirstea D.; Santo L.; Hu Y.; Tai Y.T.; Nahar S.; Mimura N.; Fabre C.; Raje N.; Munshi N.; Richardson P.; Anderson K.C.; Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010,116(17),3227-3237","journal-title":"Blood"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2009-02-200543","volume":"114","author":"Xu Y.","year":"2009","unstructured":"Xu Y.; Li J.; Ferguson G.D.; Mercurio F.; Khambatta G.; Morrison L.; Lopez-Girona A.; Corral L.G.; Webb D.R.; Bennett B.L.; Xie W.; Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009,114(2),338-345","journal-title":"Blood"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"Galustian C.","year":"2009","unstructured":"Galustian C.; Meyer B.; Labarthe M.C.; Dredge K.; Klaschka D.; Henry J.; Todryk S.; Chen R.; Muller G.; Stirling D.; Schafer P.; Bartlett J.B.; Dalgleish A.G.; The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009,58(7),1033-1045","journal-title":"Cancer Immunol Immunother"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood.V114.22.3441.3441","volume":"114","author":"Gaidarova S.L.J.","year":"2009","unstructured":"Gaidarova S.L.J.; Corral L.G.; Glezer E.; Schafer P.H.; Xie W.; Lopez-Girona A.; Cheson B.; Bennett B.; Lenalidomide alone and in combination with rituximab enhances NK cell immune synapse formation in chronic lymphocytic leukemia (CLL) cells in vitro through activation of Rho and Rac1 GTPases. Blood 2009,114(22),3441","journal-title":"Blood"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1182\/blood-2012-08-448332","volume":"121","author":"Ramsay A.G.","year":"2013","unstructured":"Ramsay A.G.; Evans R.; Kiaii S.; Svensson L.; Hogg N.; Gribben J.G.; Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013,121(14),2704-2714","journal-title":"Blood"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","volume":"115","author":"Lapalombella R.","year":"2010","unstructured":"Lapalombella R.; Andritsos L.; Liu Q.; May S.E.; Browning R.; Pham L.V.; Blum K.A.; Blum W.; Ramanunni A.; Raymond C.A.; Smith L.L.; Lehman A.; Mo X.; Jarjoura D.; Chen C.S.; Ford R.; Rader C.; Muthusamy N.; Johnson A.J.; Byrd J.C.; Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010,115(13),2619-2629","journal-title":"Blood"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3324\/haematol.2014.113217","volume":"100","author":"Fiorcari S.","year":"2015","unstructured":"Fiorcari S.; Martinelli S.; Bulgarelli J.; Audrito V.; Zucchini P.; Colaci E.; Potenza L.; Narni F.; Luppi M.; Deaglio S.; Marasca R.; Maffei R.; Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica 2015,100(2),253-262","journal-title":"Haematologica"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.exphem.2013.10.007","volume":"42","author":"Maffei R.","year":"2014","unstructured":"Maffei R.; Fiorcari S.; Bulgarelli J.; Rizzotto L.; Martinelli S.; Rigolin G.M.; Debbia G.; Castelli I.; Bonacorsi G.; Santachiara R.; Forconi F.; Rossi D.; Laurenti L.; Palumbo G.A.; Vallisa D.; Cuneo A.; Gaidano G.; Luppi M.; Marasca R.; Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Exp Hematol 2014,42(2),126-36, e1","journal-title":"Exp Hematol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1172\/JCI35017","volume":"118","author":"Ramsay A.G.","year":"2008","unstructured":"Ramsay A.G.; Johnson A.J.; Lee A.M.; Gorg\u00fcn G.; Le Dieu R.; Blum W.; Byrd J.C.; Gribben J.G.; Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008,118(7),2427-2437","journal-title":"J Clin Invest"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1182\/blood-2012-12-470005","volume":"121","author":"Shanafelt T.D.","year":"2013","unstructured":"Shanafelt T.D.; Ramsay A.G.; Zent C.S.; Leis J.F.; Tun H.W.; Call T.G.; LaPlant B.; Bowen D.; Pettinger A.; Jelinek D.F.; Hanson C.A.; Kay N.E.; Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 2013,121(20),4137-4141","journal-title":"Blood"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","volume":"18","author":"Noonan K.","year":"2012","unstructured":"Noonan K.; Rudraraju L.; Ferguson A.; Emerling A.; Pasetti M.F.; Huff C.A.; Borrello I.; Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 2012,18(5),1426-1434","journal-title":"Clin Cancer Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1084\/jem.20110132","volume":"208","author":"Ehninger A.","year":"2011","unstructured":"Ehninger A.; Trumpp A.; The bone marrow stem cell niche grows up: Mesenchymal stem cells and macrophages move in. J Exp Med 2011,208(3),421-428","journal-title":"J Exp Med"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","volume":"171","author":"Blazar B.R.","year":"2003","unstructured":"Blazar B.R.; Carreno B.M.; Panoskaltsis-Mortari A.; Carter L.; Iwai Y.; Yagita H.; Nishimura H.; Taylor P.A.; Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 2003,171(3),1272-1277","journal-title":"J Immunol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"Fenaux P.","year":"2009","unstructured":"Fenaux P.; Mufti G.J.; Hellstrom-Lindberg E.; Santini V.; Finelli C.; Giagounidis A.; Schoch R.; Gattermann N.; Sanz G.; List A.; Gore S.D.; Seymour J.F.; Bennett J.M.; Byrd J.; Backstrom J.; Zimmerman L.; McKenzie D.; Beach C.; Silverman L.R.; Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009,10(3),223-232","journal-title":"Lancet Oncol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"Kantarjian H.M.","year":"2012","unstructured":"Kantarjian H.M.; Thomas X.G.; Dmoszynska A.; Wierzbowska A.; Mazur G.; Mayer J.; Gau J.P.; Chou W.C.; Buckstein R.; Cermak J.; Kuo C.Y.; Oriol A.; Ravandi F.; Faderl S.; Delaunay J.; Lys\u00e1k D.; Minden M.; Arthur C.; Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012,30(21),2670-2677","journal-title":"J Clin Oncol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"60656","DOI":"10.18632\/oncotarget.19269","volume":"8","author":"Larocca A.","year":"2017","unstructured":"Larocca A.; Mina R.; Gay F.; Bringhen S.; Boccadoro M.; Emerging drugs and combinations to treat multiple myeloma. Oncotarget 2017,8(36),60656-60672","journal-title":"Oncotarget"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/13543784.2017.1275564","volume":"26","author":"Tvedt T.H.","year":"2017","unstructured":"Tvedt T.H.; Nepstad I.; Bruserud \u00d8.; Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Expert Opin Investig Drugs 2017,26(3),343-355","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.3389\/fimmu.2017.01918","volume":"8","author":"Lecciso M.","year":"2017","unstructured":"Lecciso M.; Ocadlikova D.; Sangaletti S.; Trabanelli S.; De Marchi E.; Orioli E.; Pegoraro A.; Portararo P.; Jandus C.; Bontadini A.; Redavid A.; Salvestrini V.; Romero P.; Colombo M.P.; Di Virgilio F.; Cavo M.; Adinolfi E.; Curti A.; ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells. Front Immunol 2017,8,1918","journal-title":"Front Immunol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12944-017-0624-1","volume":"16","author":"W\u0105tek M.","year":"2017","unstructured":"W\u0105tek M.; Durna\u015b B.; Wollny T.; Pasiarski M.; G\u00f3\u017ad\u017a S.; Marzec M.; Chabowska A.; Wolak P.; \u017bendzian-Piotrowska M.; Bucki R.; Unexpected profile of sphingolipid contents in blood and bone marrow plasma collected from patients diagnosed with acute myeloid leukemia. Lipids Health Dis 2017,16(1),235","journal-title":"Lipids Health Dis"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fonc.2016.00218","volume":"6","author":"Rodriguez Y.I.","year":"2016","unstructured":"Rodriguez Y.I.; Campos L.E.; Castro M.G.; Aladhami A.; Oskeritzian C.A.; Alvarez S.E.; Sphingosine-1 phosphate: A new modulator of immune plasticity in the tumor microenvironment. Front Oncol 2016,6,218","journal-title":"Front Oncol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2016-06-720433","volume":"129","author":"Powell J.A.","year":"2017","unstructured":"Powell J.A.; Lewis A.C.; Zhu W.; Toubia J.; Pitman M.R.; Wallington-Beddoe C.T.; Moretti P.A.; Iarossi D.; Samaraweera S.E.; Cummings N.; Ramshaw H.S.; Thomas D.; Wei A.H.; Lopez A.F.; D\u2019Andrea R.J.; Lewis I.D.; Pitson S.M.; Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood 2017,129(6),771-782","journal-title":"Blood"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T08:31:06Z","timestamp":1574929866000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170932\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":133,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2019,10,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190325095853","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}